Chemical Stability of Hydrocortisone in Topical Preparation in Proprietary VersaPro™ Cream Base by Sarkar, Arindam Basu et al.
Volume 2 | Number 3 Article 54
2011
Chemical Stability of Hydrocortisone in Topical
Preparation in Proprietary VersaPro™ Cream Base
Arindam Basu Sarkar
Richard Dudley
Srikumaran Melethil
Jonathon Speidel
Gopalkumar Markandakumar Bhatt
Follow this and additional works at: http://pubs.lib.umn.edu/innovations
INNOVATIONS in pharmacy is published by the University of Minnesota Libraries Publishing.
Recommended Citation
Sarkar AB, Dudley R, Melethil S, Speidel J, Bhatt GM. Chemical Stability of Hydrocortisone in Topical Preparation in Proprietary
VersaPro™ Cream Base. Inov Pharm. 2011;2(3): Article 54. http://pubs.lib.umn.edu/innovations/vol2/iss3/8
Original Research SCIENCE 
 
http://z.umn.edu/INNOVATIONS                         2011, Vol. 2, No. 3, Article 54                        INNOVATIONS in pharmacy   1 
 
Chemical Stability of Hydrocortisone in Topical Preparation in Proprietary VersaProTM Cream Base 
Arindam Basu Sarkar
1
, Richard Dudley
1
, Srikumaran Melethil
2
, Jonathon Speidel
1
, Gopalkumar Markandakumar Bhatt
 1
 
1
University of Findlay College of Pharmacy, 1000 North Main Street, Findlay, OH 45840 
2
Professor Emeritus, Schools of Pharmacy and Medicine, University of Missouri-Kansas City 
 
Acknowledgement:  The study was supported by grant from Medisca Pharmaceutique Inc., 6090 Henry-Bourassa West, Saint-
Laurent, QC H4R 3A6, Canada.   
 
 
Abstract 
The United States Pharmacopeia-National Formulary (USP-NF) suggests beyond use dating ((BUD) for compounded topical 
preparations containing active pharmaceutical ingredients (API) [1].  The beyond the use dates of the preparations are based on the 
conservative and empirical guidelines of USP 795.  Hydrocortisone (HC) content compounded in the VersaPro™ base cream was 
quantified using a HPLC method at time zero and after 30 and 60 days of storage at both room temperature and 4℃. The analysis 
suggests that the compounded preparations retain > 95% of the stated initial potency of HC regardless of storage conditions.  Thus 
HC creams prepared in VersaPro™ cream base can be safely assigned a beyond the use date of two months when stored at room 
temperature. 
 
 
Introduction 
Hydrocortisone (Figure 1), a glucocorticoid steroid, is used for 
its anti-inflammatory and immune modulating properties in 
both over-the-counter (OTC) and prescription only 
preparations. While several concentrations are commercially 
available in a variety of vehicles, physicians may request HC 
be compounded in various situations including temporary 
supply disruption, excipient-related patient specific 
incompatibility and non-standard concentration of 
Hydrocortisone. Moreover, the vehicle can have an impact on 
the stability and absorption of HC. The instability of HC, when 
compounded in water or polyethylene glycol ointment bases 
has been previously demonstrated [2]. Likewise, HC has been 
shown to degrade when compounded in a zinc oxide vehicle 
[3]. The United States Pharmacopeia-National Formulary 
(USP-NF) has suggested guidelines regarding the beyond use 
date for such compounded formulations. In general, the USP 
recommends beyond use dating of fourteen days for 
preparations containing water when prepared from 
ingredients in solid form and the preparation is stored in a 
cool place (2-8℃). The purpose of this study was to 
determine the stability of HC when compounded in 
VersaPro™, a proprietary vehicle with a water content that  
exceeds 75 percent. The study was conducted at time zero 
and after 30 and 60 days of incubation at both room 
temperature (RT 25℃), and under refrigeration (4℃).  Since 
the hydrocortisone preparation is intended for topical use,  
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the need for assessing microbial stability (which is routinely 
carried for parenteral products) was not felt.   
 
 
Figure 1. Chemical Structure of Hydrocortisone 
 
Materials and Methods 
Hydrocortisone USP was provided by Medisca 
Pharmaceutique Inc. Quebec, Canada. Acetonitrile (ACN)  
(Fisher Scientific, HPLC grade) was used as organic modifier in 
the mobile phase along with deionized water (18 Ω, available 
in our laboratory). All other reagents used were of analytical 
grade.  The formulation of hydrocortisone contained (i) 
micronized hydrocortisone USP (2% w/w), (ii) ethoxy diglycol 
(2% w/v) and rest VersaPro
TM
 cream base.  The required 
quantity of the hydrocortisone for 100 gm of preparation was 
levigated with the ethoxy diglycol to form a uniform 
dispersion.  The cream was then added to the dispersion 
according to the principles of geometric dilution.  The 
preparation was then divided in two equal parts and kept in a 
tightly closed 2 oz ointment jars under refrigeration (4℃) and 
room temperature (25℃) for two months. 
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Instruments 
 
A Hewlett Packard 1050 HPLC system consisting of a 
quaternary pump (Model 79852A), an autosampler (Model 
79855A), a degasser (Model G1303A), a diode-array-detector 
(Model HP1046A), a solvent tray and a desktop computer 
loaded with ChemStation software was used for our analysis.  
A Mettler AL204 electronic balance (Mettler-Toledo, 
Columbus, OH), an unguator (Cito Unguator 014, Zella-
Mehlis, Germany) were used for compounding the 
preparation. The stationary phase consisted of a Zorbax 
Eclipse Plus Column (C18, 4.6mm ID x150 mm, 3.5 μm particle 
size, 95Å pore size, pH range 2-9 (Agilent Technologies, Santa 
Clara, CA) and a compatible Zorbax pre-column.   
 
Chromatographic Conditions 
 
The mobile phase consisted of Solvent A (acetonitrile) and 
Solvent B (20 mM acetate buffer at pH 2.5). The following 
gradient elution method was used: 80% to 40% (v/v) of 
solvent B over 10 min returning to 80% (v/v) of solvent B 
from 10.01min until the end of the run at 12 min. The column 
was kept at ambient room temperature while the flow rate 
was maintained at 1.0 mL/min. The injection volume for each 
sample was 10 µL and the detection wavelength was 220 nm. 
Under the described chromatographic conditions the 
retention time of hydrocortisone was 7 minutes.   For best 
results, the column was conditioned by running the mobile 
phase (20% of solvent B) overnight at a flow rate of 0.1 
ml/min.  The chromatographic method of analysis has been 
specifically developed for analyzing hydrocortisone in the said 
VersaPro
TM
 cream.  Estrdiol was chosen as internal standard 
(IS) as both the compounds are similar in structure (and thus 
were expected to be affected by the variability in 
chromatographic conditions similarly).  Additionally, the 
compound can be easily separated from hydrocortisone. 
 
Preparation of standards and samples 
 
Primary Standard: Ten milligrams (0.01gram) of 
hydrocortisone was weighed with a margin of plus or minus 
(0.0005 gram). This quantity was placed in a volumetric flask 
and the volume was made up to 100 mL with ACN. The 
resulting solution afforded a final concentration of 100 µg/mL 
for the primary standard (PS).  
 
Internal Standard: Ten milligrams (0.01gram) of estradiol was 
weighed with a margin of plus or minus (0.0005 gram). This 
quantity was placed in a volumetric flask and the volume was 
brought to 100 mL with ACN. The resulting solution afforded 
a final concentration of 100 µg/mL for the IS.  
Secondary Standards (SS): Using the 100 µg/mL primary 
standard and 100 µg/mL IS, SS were prepared to afford 
concentrations of 10, 25, 50, and 70 µg/mL (50 µg/mL IS 
concentration, constant)  which were subsequently used in 
generation of the standard curve. 
 
Standard Curve: Secondary standards were placed in the 
autosampler and separation was initiated with an injection 
volume of 10 µL using the method previously described under 
Chromatographic conditions. Each secondary standard was 
run in sextuplet fashion to generate area under the curve 
(AUC) data.   Plots of AUC ratio (hydrocortisone/IS) versus 
concentration were generated for visual inspection. Linear 
regression analysis was performed to establish the 
concentration (µg/mL) versus area under the curve 
relationship in quantitative terms.  The concentration –AUC 
ratio relationship for hydrocortisone (figure 2) is expressed by 
the following equation:    
    y = 0.0147x+0.013 
 
Where, x = concentration of hydrocortisone in (µg/mL) and y= 
AUC ratio (hydrocortisone/ estradiol [IS]) is a dimensionless 
number.  The correlation coefficient (R
2
= 0.9941) value  
indicates a near perfect linear fit of the data (six replicates).   
The mean slope was 0.0147 with standard parametric error of  
3.26% while the intercept was 0.013 with standard 
parametric error of 104.49 %.  The accuracy and precision of 
the method were determined (Table 1). 
 
 
Table 1.  Accuracy and precision for the determination of 
hydrocortisone in VersaPro
TM 
Cream base.  a  N=6, 
calculations based on peak area ratio of hydrocortisone and 
the internal standard (estradiol).   
 
SD = Standard Deviation, RSD = Relative Standard Deviation. 
 
 
 
 
 
 
 
 
 
Calibration 
level 
Assay 
Mean
a
 Standard Accuracy 
Precision 
(RSD) 
( µg/mL )  µg/mL) Deviation % % 
10 9.98 0.008 99.79 5.04 
25 24.65 0.015 98.61 3.96 
50 50.83 0.038 101.66 4.98 
70 69.53 0.035 99.33 3.41 
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Figure 2. Standard curve. The AUC ratio 
(hydrocortisone/estradiol [IS]) vs. concentration. 
 
Two percent hydrocortisone cream prepared in VersaPro™ 
base was incubated at RT and 4℃ for 30 and 60 days. At the 
end of each incubation period, sample was accurately 
weighed, solubilized, and further diluted with ACN followed 
by separation using the chromatographic conditions 
described previously.  
 
Results and Discussion 
The data shown in table 2 are expressed as the mean and 
standard deviation of four individual samples.  The coefficient 
of variation of the concentration of hydrocortisone is below 
3.5% of the mean concentration and suggests good precision 
of the analytical method. 
 
Beyond use dating ensures safety and efficacy of a 
compounded preparation, provided the use does not extend 
past the stated date.   It is evident from the table that the 
preparations maintained adequate (>95% of the labeled 
amount) chemical potency over both temperatures and time 
intervals.  Interestingly, the 60 day sample incubated at 4℃ 
possesses the highest degree of variance. It is not surprising 
that the 60 day sample came back with a lower degree of 
retained potency given the longer incubation time.  The 
Chemical stability data obtained through this study is also 
supported by the commercial over-the-counter 
hydrocortisone creams which suggest expiry date of 18-24 
months following manufacture. 
 
Conclusion 
The use of VersaPro™ base does not enhance the degradation 
of hydrocortisone over the tested time periods regardless of 
temperature, and despite its high water content. The beyond- 
the-use date of compounded topical hydrocortisone    cream 
prepared in VersaPro
TM
 cream base can thus be safely 
assigned to be two months when stored in room 
temperature.  The stability data of the APIs in a particular 
cream base is thus useful in ensuring optimum beyond the 
use date minimizing the medication wastage, while ensuring 
safety and efficacy of the preparation. 
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Table 2. Stability data of hydrocortisone 2% at room temperature and 4℃ over 30 and 60 days. 
 
 
 
Time zero 
Day 30 
at RT 
Day 30 
at 4⁰C 
Day 60 
at RT 
Day 60 
at 4⁰C 
Percent of the labeled claim 98.5 99.5 99.5 99.5 96 
Standard Deviation (w/w) 0.06 0.02 0.01 0.06 0.1 
Coefficient of Variation (% of Mean) 3.1 1.1 0.7 2.9 5 
Number of repetition 8 4 4 4 4 
